Qilian International Holding Group

Qilian International Holding Group Ltd. is a pharmaceutical and chemical company. It focuses on the research, development, manufacture, marketing, and sale of oxytetracycline products, licorice products, traditional Chinese medicine derivatives product, heparin product, sausage casings, and fertilizers. The Licorice products include Gan Di Xin, Qilian Shan Licorice Extract, and Qilian Shan Licorice Liquid Extract. The Oxytetracycline products consists of Qilian Shan Oxytetracycline Tablets and Qilian Shan Oxytetracycline Active Pharmaceutical Ingredients (API). The TCMD product includes Ahan antibacterial paste, which is made from a mixture of traditional Chinese herbal ingredients. The heparin product includes Heparin Sodium Preparations. The Sausage Casings products include Zhu Xiaochang Sausage Casings, which are all-natural food products used for culinary purposes. The Fertilizer products is composed of Xiongguan Organic Fertilizer and Xiongguan Organic-Inorganic Compound Fertilizer. The company was founded on February 7, 2019 and is headquartered in Jiuquan, China.

New York, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, is a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of the initial public offering (“IPO”) for its client Qilian International Holding Group Limited (the “Company”), marking the first IPO in 2021 to which Univest acts as the sole book-running manager. A total of 5,750,000 ordinary shares of the Company, including 750,000 ordinary shares pursuant to Univest's full exervise of the over-allotment option, are offered at a public offering price of $5.00 per share, raising aggregate gross proceeds of $28,750,000, before deducting underwriting discounts and other related expenses. The ordinary shares began trading on the Nasdaq Global Market on January 12, 2021 under the ticker symbol “QLI”.

Univest Securities, LLC. Announces Closing of IPO for its Client Qilian International Holding Group Limited (Nasdaq: QLI)

Jiuquan, China, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (the “Company”) (Nasdaq: QLI), a China-based pharmaceutical and chemical products manufacturer, today announced the closing of its initial public offering ("Offering") of 5,000,000 ordinary shares at a public offering price of US$5.00 per share.

Qilian International Holding Group Limited Announces Closing of Initial Public Offering

Qilian (QLI) is catching the eyes of investors on Tuesday as shares of its stock started trading today via the company's IPO. The post Qilian IPO: 10 Things for Potential QLI Stock Investors to Know About the Chinese Pharma appeared first on InvestorPlace.

Qilian IPO: 10 Things for Potential QLI Stock Investors to Know About the Chinese Pharma

Jiuquan, China, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced the pricing of its initial public offering ("Offering") of 5,000,000 ordinary shares at a public offering price of US$5.00 per share. The ordinary shares have been approved for listing on the Nasdaq Global Market and are expected to commence trading on January 12, 2021 under the ticker symbol “QLI”.

News for Qilian International Holding Group Stock (QLI)